A number of other brokerages have also recently issued reports on DCPH. Piper Jaffray Companies set a $55.00 price objective on shares of Deciphera Pharmaceuticals and gave the company a buy rating in a research note on Monday, September 30th. Canaccord Genuity reaffirmed a buy rating and issued a $65.00 price objective (up previously from $50.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 14th. Jefferies Financial Group started coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, September 30th. They issued a buy rating and a $47.00 price objective for the company. Leerink Swann raised shares of Deciphera Pharmaceuticals from an underperform rating to a market perform rating in a research note on Tuesday, October 29th. Finally, Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $40.00 price objective for the company in a research note on Friday, October 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $49.31.
Shares of NASDAQ DCPH traded up $0.33 during midday trading on Tuesday, hitting $47.47. The company’s stock had a trading volume of 540,000 shares, compared to its average volume of 406,608. Deciphera Pharmaceuticals has a one year low of $19.06 and a one year high of $48.00. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of -16.83 and a beta of 1.96. The stock has a fifty day moving average price of $36.77 and a 200 day moving average price of $28.93.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.09). As a group, analysts expect that Deciphera Pharmaceuticals will post -4.29 EPS for the current year.
In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 11,250 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel C. Martin sold 3,000 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $35.56, for a total transaction of $106,680.00. Insiders have sold a total of 634,677 shares of company stock valued at $24,390,512 in the last three months. 7.02% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of Montreal Can purchased a new stake in Deciphera Pharmaceuticals during the 2nd quarter valued at $28,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Deciphera Pharmaceuticals by 162.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,737 shares of the company’s stock valued at $59,000 after buying an additional 1,074 shares during the period. Tower Research Capital LLC TRC purchased a new stake in Deciphera Pharmaceuticals during the 2nd quarter valued at $64,000. JPMorgan Chase & Co. raised its holdings in Deciphera Pharmaceuticals by 89.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after purchasing an additional 1,913 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Deciphera Pharmaceuticals by 214.8% in the 2nd quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after purchasing an additional 5,366 shares in the last quarter. 45.71% of the stock is owned by institutional investors and hedge funds.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
See Also: What is a capital gain?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.